Prediction of Chronic Allograft Nephropathy
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 23, 2011
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
mRNA profiling of urinary cells is fast evolving as a non-invasive substitute for invasive biopsy procedures employed for predicting renal allograft outcomes. This technique has been successfully used to develop biomarkers of acute rejection, but has not been evaluated for the diagnosis of allograft fibrosis.
The progressive scarring process of an allograft, called chronic allograft nephropathy (CAN), remains the chief cause of kidney transplant failure. We have shown by immunohistochemistry that epithelial changes suggestive of epithelial-to-mesenchymal transition (EMT) in early protocol ...
Gender
ALL
Eligibility criteria
- Inclusion criteria :
- • male and female adult recipients
- • patients undergoing primary or re-do deceased-donor or living-donor kidney transplantation
- • ability to provide informed consent
- Exclusion criteria :
- • patients undergoing combined organ transplantation
- • Contraindication to protocol allograft biopsy
- • Inability or unwillingness of a participant to provide informed consent.
- • HCV infected
- • HIV infected
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Dany Anglicheau, MD, PhD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials